MBI-006-COMUNITY: Combined AlloStim+Anti-PD-L1 in MSS Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Sponsor: Mirror Biologics, Inc.
Full Title
Protocol MBI-006-COMUNITY: Phase II Open-Label Study to Assess the Safety and Efficacy of AlloStim® + Anti-PDL1 as Fourth Line Therapy for MSS Metastatic Colorectal Cancer
Study Treatment
AlloStim® +/- anti-PDL1 antibody avelumab
AlloStim®, is a patented, “off-the-shelf”, bioengineered, non-genetically altered, ex-vivo differentiated and expanded CD4+ Th1-like memory cell with anti-CD3/anti-CD28 coated microbeads attached (a/k/a Bioengineered Allograft Cells or “BAG” cells). AlloStim® cells produce type 1 cytokines such as interferon-gamma, GM-CSF and TNF-alpha and express high density CD40L. AlloStim® has potent immunomodulatory properties that are used to reverse engineer immune mechanisms and imprint them upon the immune systems of patients with cancer.
Eligibility/Info
Microsatellite stable/Mismatch repair proficient metastatic colorectal cancer that has come back or continued to grow after at least 2 lines of systemic therapy that included oxaliplatin, irinotecan, and TAS-102 or regorafenib.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
